A bill to amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for prescription drugs.

Bill 118 s 4691 aims to make changes to the Internal Revenue Code of 1986 by denying the deduction for advertising and promotional expenses related to prescription drugs. This means that pharmaceutical companies would no longer be able to deduct the costs of advertising and promoting their prescription drugs from their taxable income.

The bill is intended to address concerns about the high costs of prescription drugs and the role that advertising plays in driving up these costs. By eliminating the tax deduction for advertising expenses, the hope is that pharmaceutical companies will be less incentivized to spend large amounts of money on advertising, which could ultimately lead to lower drug prices for consumers.

Supporters of the bill argue that it is a necessary step to rein in the rising costs of prescription drugs and make healthcare more affordable for all Americans. Critics, however, argue that limiting the ability of pharmaceutical companies to advertise their products could stifle innovation and hinder the development of new and potentially life-saving medications. Overall, Bill 118 s 4691 represents a significant proposed change to the tax code that could have far-reaching implications for the pharmaceutical industry and the healthcare system as a whole. It will be important to closely monitor the progress of this bill as it moves through the legislative process.